Kodiak Sciences (NASDAQ:KOD – Get Free Report) and MiMedx Group (NASDAQ:MDXG – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.
Institutional and Insider Ownership
89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 44.4% of Kodiak Sciences shares are held by company insiders. Comparatively, 2.5% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Kodiak Sciences and MiMedx Group”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kodiak Sciences | N/A | N/A | -$229.97 million | ($4.17) | -10.88 |
| MiMedx Group | $418.63 million | 1.51 | $48.58 million | $0.04 | 108.50 |
MiMedx Group has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Kodiak Sciences and MiMedx Group, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kodiak Sciences | 1 | 1 | 6 | 0 | 2.62 |
| MiMedx Group | 1 | 0 | 6 | 0 | 2.71 |
Kodiak Sciences currently has a consensus target price of $48.14, indicating a potential upside of 6.11%. MiMedx Group has a consensus target price of $8.50, indicating a potential upside of 95.85%. Given MiMedx Group’s stronger consensus rating and higher probable upside, analysts clearly believe MiMedx Group is more favorable than Kodiak Sciences.
Risk & Volatility
Kodiak Sciences has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.
Profitability
This table compares Kodiak Sciences and MiMedx Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kodiak Sciences | N/A | -253.85% | -81.48% |
| MiMedx Group | 1.76% | 12.09% | 9.22% |
Summary
MiMedx Group beats Kodiak Sciences on 9 of the 12 factors compared between the two stocks.
About Kodiak Sciences
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
About MiMedx Group
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company’s products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
